190 related articles for article (PubMed ID: 3925558)
1. Cellular and clinical pharmacology of low-dose ara-C.
Kufe DW; Griffin JD; Spriggs DR
Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.
Kufe DW; Munroe D; Herrick D; Egan E; Spriggs D
Mol Pharmacol; 1984 Jul; 26(1):128-34. PubMed ID: 6431261
[TBL] [Abstract][Full Text] [Related]
3. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
[TBL] [Abstract][Full Text] [Related]
4. Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3.
Ishikura H; Okazaki T; Mochizuki T; Izumi Y; Tashima M; Sawada H; Uchino H
Exp Hematol; 1985 Nov; 13(10):981-8. PubMed ID: 3932088
[TBL] [Abstract][Full Text] [Related]
5. Effect of ara-A on differentiation and proliferation of HL-60 cells.
Munroe D; Sugiura M; Griffin J; Kufe D
Leuk Res; 1984; 8(3):355-61. PubMed ID: 6589455
[TBL] [Abstract][Full Text] [Related]
6. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.
Luisi-DeLuca C; Mitchell T; Spriggs D; Kufe DW
J Clin Invest; 1984 Sep; 74(3):821-7. PubMed ID: 6590568
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells.
Robichaud NJ; Fram RJ
Biochem Pharmacol; 1987 May; 36(10):1673-7. PubMed ID: 3109427
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanism of action of cytosine arabinoside.
Kufe DW; Major PP
Med Pediatr Oncol; 1982; 10 Suppl 1():49-67. PubMed ID: 6761569
[TBL] [Abstract][Full Text] [Related]
10. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
Motta MR; Baccarani M; Rizzi S; Fanin R; Fasola G; Poluzzi C; Tura S
Blut; 1987 May; 54(5):299-306. PubMed ID: 3567369
[TBL] [Abstract][Full Text] [Related]
11. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.
Griffin J; Munroe D; Major P; Kufe D
Exp Hematol; 1982 Oct; 10(9):774-81. PubMed ID: 6816625
[TBL] [Abstract][Full Text] [Related]
12. In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.
Chan CS; Schechter GP
Cancer Chemother Pharmacol; 1989; 23(2):87-94. PubMed ID: 2910516
[TBL] [Abstract][Full Text] [Related]
13. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.
Fram RJ; Kufe DW
Cancer Res; 1982 Oct; 42(10):4050-3. PubMed ID: 6809309
[TBL] [Abstract][Full Text] [Related]
14. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
Bhalla K; MacLaughlin W; Cole J; Arlin Z; Baker M; Graham G; Grant S
Blood; 1987 Aug; 70(2):568-71. PubMed ID: 3607288
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of low-dose cytosine arabinoside.
Spriggs D; Griffin J; Wisch J; Kufe D
Blood; 1985 May; 65(5):1087-9. PubMed ID: 3995167
[TBL] [Abstract][Full Text] [Related]
16. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
17. A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine.
Huang CL; Deng ML; Guo RJ; Wu MT; Liu FZ; Liang YM; Qiao QD
Leukemia; 1988 Aug; 2(8):518-22. PubMed ID: 3412024
[TBL] [Abstract][Full Text] [Related]
18. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
[TBL] [Abstract][Full Text] [Related]
19. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
20. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
